<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508947</url>
  </required_header>
  <id_info>
    <org_study_id>WVE-DMDX51-001</org_study_id>
    <nct_id>NCT03508947</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wave Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wave Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, double-blind, placebo-controlled, single ascending dose cohort study to
      evaluate the safety, tolerability, and plasma concentrations of WVE-210201 in ambulatory and
      non-ambulatory male pediatric patients with DMD amenable to exon 51 skipping intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Actual">March 6, 2019</completion_date>
  <primary_completion_date type="Actual">March 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of patients with adverse events (AEs)</measure>
    <time_frame>Day 1 to Day 85 (end of study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Severity of AEs</measure>
    <time_frame>Day 1 to Day 85 (end of study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of patients with serious AEs (SAEs)</measure>
    <time_frame>Day 1 to Day 85 (end of study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability: Number of patients who withdraw due to AEs</measure>
    <time_frame>Day 1 to Day 85 (end of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1, Day 2, and Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of occurrence of Cmax (tmax)</measure>
    <time_frame>Day 1, Day 2, and Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area under the plasma concentration-time curve (AUC 0-t)</measure>
    <time_frame>Day 1, Day 2, and Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>WVE-210201 (Dose A) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-210201 (Dose B) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-210201 (Dose C) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-210201 (Dose D) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-210201 (Dose E) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WVE-210201</intervention_name>
    <description>WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
    <arm_group_label>WVE-210201 (Dose A) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose B) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose C) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose D) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose E) or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium Chloride</description>
    <arm_group_label>WVE-210201 (Dose A) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose B) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose C) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose D) or placebo</arm_group_label>
    <arm_group_label>WVE-210201 (Dose E) or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Duchenne muscular dystrophy (DMD) based on clinical phenotype with
             increased serum creatine kinase

          -  Documented mutation in the Dystrophin gene associated with DMD that is amenable to
             exon 51 skipping

          -  Ambulatory or non-ambulatory male patients aged ≥5 - ≤18 years

          -  Stable pulmonary and cardiac function as measured by:

               1. Reproducible percent predicted forced vital capacity (FVC) ≥50%

               2. Left ventricular ejection fraction (LVEF) &gt;55% in patients &lt;10 years of age and
                  &gt;45% in patients ≥10 years of age, as measured (and documented) by echocardiogram
                  within one year prior to enrollment into the study.

        Exclusion Criteria:

          -  Severe cardiomyopathy; cardiomyopathy that is managed by angiotensin-converting enzyme
             (ACE) inhibitors or beta blockers is acceptable provided the patient meets the LVEF
             inclusion criteria.

          -  Need for mechanical or non-invasive ventilation OR anticipated need for mechanical or
             non-invasive ventilation within the next year, in the opinion of the Investigator.

          -  Changes in nutritional or herbal supplements or concomitant medications within 1 month
             prior to Screening visit or plans to modify dose or regimen during the study.

          -  Currently on anticoagulants or antithrombotics.

          -  Received treatment with eteplirsen or ataluren within the past 14 weeks.

          -  Received prior treatment with drisapersen.

          -  Received any investigational drug within the past 3 months or 5 half-lives, whichever
             is longer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Panzara, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Wave Life Sciences Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rare Disease Research, LLC.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de la Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C di Neurologia e Malattie Neuromuscolari Centro Clinico Nemo Sud</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Immunologia Pediatrica</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radbound University Nijmegen Medical Care</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evelina London Children's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Institute of Child Health &amp; Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

